Drug intelligence / Profile preview

TRI-1144

Development stage: Preclinical
Lead developer: Alexion Pharmaceuticals
Modality: Peptides
Administration: Subcutaneous

Overview

TRI-1144 is a second-generation HIV-1 fusion inhibitor peptide consisting of 38 amino acids. Developed by Trimeris, it is designed to block the entry of HIV-1 into host cells by targeting the viral fusion machinery. The peptide is an optimized version of earlier fusion inhibitors, such as enfuvirtide, intended to provide increased potency and a higher genetic barrier to resistance. Research has explored the use of half-life extension technologies, specifically PEGylation using β-eliminative linkers, to improve its pharmacokinetic profile and enable less frequent dosing (e.g., weekly administration).

Targets

HIV-1 gp41 NHR (HIV-1 gp41 N-terminal heptad repeat region)

Beyond the preview

Go deeper on TRI-1144.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRI-1144.

Explore the full profile